SCOTTSDALE, AZ -- (MARKET WIRE) -- April 30, 2007 -- ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBO), announced today the appointment of Frederick "Skip" M. Burkle, Jr. to its Bioterrorism/Pandemic Influenza Advisory Board. Dr. Burkle is internationally recognized as an expert in infectious diseases in developing countries, management of humanitarian emergencies and disaster medicine, and for his work as a physician, professor and author. Dr. Burkle's expertise will be valuable in the planning and implementation of educational activities surrounding ImmuneRegen's Homspera and in guiding the development of Viprovex and Radilex for the potential use in international crises, including those related to biodefense/Pandemic Flu related causes.
